SEOUL, Nov. 17 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. said Tuesday it has signed a long-term agreement with U.S. pharmaceutical firm Eli Lilly and Company to manufacture a novel coronavirus-neutralizing antibody. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will provide Eli Lilly’s investigational neutralizing antibody for the treatment of [...]
SEOUL, Sept. 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Tuesday it has signed a long-term supply agreement, valued at approximately US$330.8 million, with British-Swedish bio giant AstraZeneca Plc. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its third plant [...]
SEOUL, Aug. 11 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s largest conglomerate Samsung Group, said Tuesday that it will build a fourth plant in the country in response to rising manufacturing demand. The 1.7 trillion-won (US$1.4 billion) plant in Songdo, western Incheon, will have a bioreactor capacity of 256,000 liters, the [...]
SEOUL, July 21 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s largest conglomerate Samsung Group, said Tuesday that it shifted to the black in the second quarter from a year earlier, as costs decreased on the back of an improvement in factory utilization and increased sales. The company posted a net profit [...]
SEOUL, May 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Friday it has signed a tieup deal with multinational drug maker GlaxoSmithKline Plc. (GSK) to manufacture a GSK biosimilar product. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will commercially produce CSK’s lupus treatment, Benlysta, starting in 2022. The [...]
SEOUL, April 10 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of South Korea’s Samsung Group, said Friday that it has clinched a US$362 million deal to manufacture a candidate treatment for the novel coronavirus. Under the deal, Samsung BioLogics will start full-scale production of U.S. drug firm Vir Biotechnology’s candidate COVID-19 treatment that is [...]
SEOUL, Jun. 11 (Korea Bizwire) — Chung Hyun-ho, president of Samsung Electronics, was questioned by prosecutors on Tuesday about his suspected involvement in alleged accounting fraud at the company’s biotech affiliates. The 59-year-old Chung, known as one of the closest aides to Samsung Electronics Vice Chairman Lee Jae-yong, arrived at the Seoul Central District Prosecutors [...]
SEOUL, Nov. 19 (Korea Bizwire) – Retail investors are estimated to hold more than 3 trillion won worth of Samsung BioLogics Co. shares, whose trading was suspended last week over window-dressing, a corporate researcher said Monday. As of last Wednesday, individual investors owned an estimated 9.6 million shares of Samsung BioLogics, or 14.53 percent, according [...]
SEOUL, May 8 (Korea Bizwire) — South Korea’s major biopharmaceutical firm Samsung BioLogics Co., which has been embroiled in an alleged violation of accounting rules, on Tuesday expressed concern over the financial watchdog’s disclosure of sensitive information. “We express deep concern and regret over the situation where sensitive information surrounding the case, which is under [...]
SEOUL, Dec. 13 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Biologics Co. said Wednesday it has won approval from European health authorities to manufacture drugs at its plant in Europe. The European Medicines Agency (EMA) accepted Samsung Biologics’ manufacturing application to make 152,000 liters of biosimilars at the plant, officials said. The approval comes [...]